The Canadian subsidiary claims success in its pivotal trial, though capacity restraints will limit the jab’s role for now.
Among developers that arrived on the market via reverse mergers, big success stories are hard to find.
A project from SK Bioscience and Glaxo started phase 3 this week, but it is far from the only late-stage candidate.
Sanofi’s $3.2bn move for Translate Bio leaves Arcturus as one of the few affordable independent mRNA players.
Meanwhile, Ocugen hopes that Covaxin's India data will be enough for US approval.